BRIACELL THERAPEUTICS CORP (BCT.CA) Stock News

Canada - TSX:BCT - CA1079303071 - Common Stock

17.18 CAD

-0.42 (-2.39%)

Last: 10/10/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCT.CA Latest News, Press Relases and Analysis

All

Press Releases

9 hours ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

10 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Announces Proposed Effective Date of Share Consolidation

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Announces Proposed Effective Date of Share Consolidation

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

3 months ago - By: BriaCell Therapeutics Corp.; BriaPro Therapeutics Corp. - Mentions: BCTX

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Closing of $15 million Public Offering

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell CEO Letter to Shareholders

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

7 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

7 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

8 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

8 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Closing of Public Offering

8 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Pricing of Public Offering

8 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCTX

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares